Safety and efficacy of cathodal transcranial direct current stimulation in patients with Lennox Gastaut Syndrome: An open-label, prospective, single-center, single-blinded, pilot study

被引:2
|
作者
San-Juan, Daniel [1 ]
Ruiz, Axel Galindo [1 ]
Arriola, Armando Baigts [1 ]
Pesqueira, Gerardo Quinones [1 ]
Ruffini, Giulio [2 ]
Trenado, Carlos [3 ]
机构
[1] Natl Inst Neurol & Neurosurg Mexico, Dept Clin Neurophysiol, Mexico City, DF, Mexico
[2] Neuroelectrics Corp, Cambridge, MA USA
[3] Heinrich Heine Univ, Fac Med, Inst Clin Neurosci & Med Psychol, Dusseldorf, Germany
来源
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY | 2022年 / 100卷
关键词
tDCS; Lennox Gastaut syndrome; Seizure; Epilepsy; Transcranial direct current stimulation; Refractory seizure; TEMPORAL-LOBE EPILEPSY; MOTOR CORTEX EXCITABILITY; SEIZURE FREQUENCY; DC POLARIZATION; TRIAL; FEASIBILITY; MODULATION; MECHANISMS; PLASTICITY; SHIFTS;
D O I
10.1016/j.seizure.2022.06.009
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose: Lennox-Gastaut Syndrome (SLG) is a severe form of childhood refractory epilepsy. Only one pilot study has been conducted using cathodal transcranial direct current stimulation (c-tDCs; 2mAx30minx5days) in LGS with promising results (-99% seizure reduction at 5 days). Our aim was to explore and replicate the efficacy and safety of 10 daily sessions of c-tDCs in SLG. Methods: We conducted a one-blinded, single-center pilot clinical study of c-tDCs (2mAx 30 min x 10 days), applied over the highest amplitude or frequent epileptiform interictal discharges areas using scalp EEG re-cordings without changes in their treatments. The tDCS device used was Enobio EEG (R) (Neuroelectrics, Barce-lona, Spain). The primary outcome was based on the seizure frequency using seizure diaries before, during 10 days of treatment, and then on a 4 and 8 weeks of follow-up. The rate of adverse events was recorded as a secondary outcome. Descriptive statistics and Wilcoxon signed-rank test were used Results: Twenty-four patients were enrolled. The mean age was 10.1 +/- 5.8 years old and 75% male. All the patients had severe mental retardation and abnormal neurological examinations. A significant median percentual seizure frequency reduction was found: 68.12% (p = 0.05) at 1 week, 68.12% (p = 0.002) in the second week. We found no significant reduction at 1 and 2 months; mainly tonic and atonic seizures were reduced significantly at all times. Only mild self-limited side effects were recorded mainly itching and erythema in the application zone Conclusion: Ten sessions of c-tDCs in combination with pharmacologic treatment in LGS is safe and appears to reduce significatively tonic and atonic seizure frequency at 2 months of follow-up.
引用
收藏
页码:44 / 50
页数:7
相关论文
共 50 条
  • [41] Adjunctive home-based transcranial direct current stimulation treatment for major depression with real-time remote supervision: An open-label, single-arm feasibility study with long term outcomes
    Woodham, Rachel D.
    Rimmer, Rachael M.
    Young, Allan H.
    Fu, Cynthia H. Y.
    JOURNAL OF PSYCHIATRIC RESEARCH, 2022, 153 : 197 - 205
  • [42] Efficacy of Transcranial Direct Current Stimulation-Enhanced Mindfulness-Based Program for Chronic Pain: a Single-Blind Randomized Sham Controlled Pilot Study
    Elizabeth McCallion
    Charles S. H. Robinson
    Vincent P. Clark
    Katie Witkiewitz
    Mindfulness, 2020, 11 : 895 - 904
  • [43] The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study
    Faggiano, Antongiulio
    Modica, Roberta
    Severino, Rosa
    Camera, Luigi
    Fonti, Rosa
    Del Prete, Michela
    Chiofalo, Maria Grazia
    Aria, Massimo
    Ferolla, Piero
    Vitale, Giovanni
    Pezzullo, Luciano
    Colao, Annamaria
    ENDOCRINE, 2018, 62 (01) : 46 - 56
  • [44] Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single-arm, open-label, phase 2, multicenter study
    Zhang, Yi
    Zhou, Hu
    Duan, Minghui
    Gao, Sujun
    He, Guangsheng
    Jing, Hongmei
    Li, Junmin
    Ma, Liangming
    Zhu, Huanling
    Chang, Chunkang
    Du, Xin
    Hong, Mei
    Li, Xin
    Liu, Qingchi
    Wang, Wei
    Xu, Na
    Yang, Haiping
    Lu, Binhua
    Yin, Hewen
    Wu, Liqing
    Suo, Shanshan
    Zhao, Qingwei
    Xiao, Zhijian
    Jin, Jie
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, : 1588 - 1597
  • [45] Efficacy and safety of perampanel as early add-on therapy in Chinese patients with focal-onset seizures: a multicenter, open-label, single-arm study
    Gao, Lehong
    Lu, Qiang
    Wang, Zan
    Yue, Wei
    Wang, Guoping
    Shao, Xiaoqiu
    Guo, Yi
    Yi, Yonghong
    Hong, Zhen
    Jiang, Yuwu
    Xiao, Bo
    Cui, Guiyun
    Gao, Feng
    Hu, Jiasheng
    Liang, Jianmin
    Zhang, Meiyun
    Wang, Yuping
    FRONTIERS IN NEUROLOGY, 2023, 14
  • [46] Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are relapsed or refractory to ruxolitinib: A single-arm, open-label, phase 2, multicenter study
    Zhang, Yi
    Zhang, Qike
    Liu, Qingchi
    Dang, Huibing
    Gao, Sujun
    Wang, Wei
    Zhou, Hu
    Chen, Yuqing
    Ma, Liangming
    Wang, Jishi
    Yang, Haiping
    Lu, Binhua
    Yin, Hewen
    Wu, Liqing
    Suo, Shanshan
    Zhao, Qingwei
    Tong, Hongyan
    Jin, Jie
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (10) : 1579 - 1587
  • [47] Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study
    Beran, RG
    Berkovic, SF
    Black, AB
    Danta, G
    Hiersemenzel, R
    Schapel, GJ
    Vajda, FJE
    EPILEPSY RESEARCH, 2005, 63 (01) : 1 - 9
  • [48] Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study
    Zhang, Yan
    Xu, Junying
    Wang, Qiong
    Ling, Guohong
    Mao, Yong
    Cai, Maohuai
    Yang, Yang
    Mei, Jingfeng
    Han, Zhengxiang
    Feng, Jifeng
    Wu, Yuan
    Shi, Lin
    Wen, Shaodi
    Shen, Bo
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (11)
  • [49] Efficiency and Safety of the Selective Relaxant Binding Agent Adamgammadex Sodium for Reversing Rocuronium-Induced Deep Neuromuscular Block: A Single-Center, Open-Label, Dose-Finding, and Phase IIa Study
    Zhao, Yanhua
    Chen, Sifan
    Huai, Xiaorong
    Yu, Zhangjie
    Qi, Youmiao
    Qing, Jie
    Yu, Weifeng
    Su, Diansan
    FRONTIERS IN MEDICINE, 2021, 8
  • [50] Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study
    McDonnell, David P.
    Landry, John
    Detke, Holland C.
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2014, 29 (06) : 322 - 331